The FDA has approved a new indication for Kogenate FS (antihemophilic factor VIII recombinant), from Bayer HealthCare, for routine prophylaxis...
Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease. This product is indicated for adults, adolescents and children of all ages.
Bayer has received approval from the European Commission of Kovaltry for the treatment of hemophilia A in patients of all...
The FDA has approved Bayer’s Kovaltry (recombinant Factor VIII), for the treatment of hemophilia A in children and adults. The...
Orion Corporation has entered into a global partnership with Bayer for the development and commercialization of the compound ODM-201, an...
Bayer HealtCare and Janssen Pharmaceuticals have submitted a supplemental New Drug Application to the FDA seeking approval for the use...
Bayer AG and BlueRock Therapeutics have announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held...
On 25th July 2013, the CHMP adopted a positive opinion recommending a variation to the terms of the marketing authorisation...
Bayer HealthCare announced that the European Commission (EC) on 15 November 2013 has granted marketing authorisation for Xofigo 1000 kBq/ml,...
The FDA has on 27th September 2012 approved Stivarga (regorafenib) from Bayer HealthCare and Onyx Pharma for the treatment of...